Table 2.

RAS signaling pathway gene mutations in tumor samples from 212 patients with EGFR-mutant lung cancer and acquired resistance to EGFR TKIs

InstitutionEGFR T790MNRASKRASBRAFMEK1
MSKCC*57/1030/1030/1030/1030/103
Vanderbilt-Ingram Cancer Center8/80/80/81/80/8
Massachusetts General Hospital42/840/840/841/840/35
Others§n/d0/17n/dn/dn/d
Total107/195 (54.9%)0/2120/1952/195 (1.0%)0/146
  • n/d, no data.

  • *Sixty-eight MSKCC patient samples were assessed by a mass spectrometry-based (Sequenom) assay (ref. 39), and 35 samples were assessed using a SNaPshot-based assay (ref. 32).

  • Eight samples were analyzed at Vanderbilt-Ingram Cancer Center by the SNaPshot assay.

  • Eighty-four samples were analyzed at Massachusetts General Hospital by SNapshot assay (ref. 38).

  • §Seventeen samples were analyzed for NRAS mutations by direct sequencing at other institutions (nine patients at Okayama University, Japan, five patients at National Taiwan University Hospital, and three patients at the Max Planck Institute, Cologne, Germany).